Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 8/20 | 0.47 |
| ▸ | TTK | P33981 | 5/20 | 0.45 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16980774 | 0.86 | BUB1 (0.51) | BUB1TTKMAPT | |
| SCHEMBL16973231 | 0.84 | BUB1 (0.46) | BUB1TTK | |
| SCHEMBL16973294 | 0.83 | TTK (0.62) | BUB1TTKRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL16980889 | 0.82 | BUB1 (0.46) | BUB1TTKMEN1KMT2A | |
| SCHEMBL4875132 | 0.79 | RAB9A (0.49) | RAB9ANPC1SMN1; SMN2NAMPTMAPT | |
| SCHEMBL16980671 | 0.79 | BUB1 (0.47) | BUB1TTKNAMPTMAPT | |
| SCHEMBL15921625 | 0.79 | BUB1 (0.70) | BUB1TTKRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL16980898 | 0.77 | BUB1 (0.44) | BUB1TTK | |
| SCHEMBL16972987 | 0.76 | STAT3 (0.47) | RAB9ANPC1SMN1; SMN2NAMPTMAPT | |
| SCHEMBL15921028 | 0.76 | BUB1 (0.59) | BUB1TTKRAB9ANPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334899-A1 | AMINO-SUBSTITUTED ISOTHIAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-23 | — | — | US | claimed |
| EP-3099682-A1 | AMINO-SUBSTITUTED ISOTHIAZOLES | Bayer Pharma Aktiengesellschaft (DE) | 2016-12-07 | — | — | EP | claimed |
| EP-2980088-A1 | Amino-substituted isothiazoles | Bayer Pharma Aktiengesellschaft (DE) | 2016-02-03 | — | — | EP | claimed |
| WO-2015113920-A1 | AMINO-SUBSTITUTED ISOTHIAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-06 | — | — | WO | claimed |
| US-20170334899-A1 | AMINO-SUBSTITUTED ISOTHIAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-23 | — | — | US | disclosed |
| US-20170334899-A1 | AMINO-SUBSTITUTED ISOTHIAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-23 | — | — | US | disclosed |
| EP-2980088-A1 | Amino-substituted isothiazoles | Bayer Pharma Aktiengesellschaft (DE) | 2016-02-03 | — | — | EP | disclosed |
| EP-2980088-A1 | Amino-substituted isothiazoles | Bayer Pharma Aktiengesellschaft (DE) | 2016-02-03 | — | — | EP | disclosed |
| WO-2015113920-A1 | AMINO-SUBSTITUTED ISOTHIAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334899-A1 | AMINO-SUBSTITUTED ISOTHIAZOLES | BRCA1, TP53, SULT2A1 | BUB1 510/4885TTK 3488/4885RAB9A 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.